Difference between revisions of "Darbepoetin alfa (Aranesp)"
Jump to navigation
Jump to search
m |
m |
||
| Line 20: | Line 20: | ||
[[Category:Hematopoietic growth factors]] | [[Category:Hematopoietic growth factors]] | ||
[[Category:Erythrocyte growth factors]] | [[Category:Erythrocyte growth factors]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2001]] | ||
Revision as of 17:19, 3 November 2014
General information
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.[1][2][3]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Darbepoetin alfa (Aranesp) package insert pages 39-46[1]
- Darbepoetin alfa (Aranesp) patient drug information (Chemocare)[5]
- Darbepoetin alfa (Aranesp) patient drug information (UpToDate)[6]
Also known as
Nespo
References
- ↑ 1.0 1.1 1.2 Darbepoetin alfa (Aranesp) package insert
- ↑ Darbepoetin alfa (Aranesp) package insert (locally hosted backup)
- ↑ Aranesp manufacturer's website
- ↑ ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Darbepoetin alfa (Aranesp) patient drug information (Chemocare)
- ↑ Darbepoetin alfa (Aranesp) patient drug information (UpToDate)